Search
Pegdinetanib
go.drugbank.com/drugs/DB05931InvestigationalCT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis
Categories: Vascular Endothelial Growth Factor Receptor-2, antagonists & inhibitorsSiagoside
go.drugbank.com/drugs/DB12351InvestigationalSygen appears to be beneficial in patients with severe spinal cord injury. … It is a naturally occurring substance in the nerve cell’s membrane that is thought to play a role in cell growth, development, and repair.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThese cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. … These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.
Silver sulfadiazine
go.drugbank.com/drugs/DB05245ApprovedInvestigationalVet approvedSilver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Products: SULFADIAZINA DE PLATA, SULFADIAZINA DE PLATA CREMAAdPEDF
go.drugbank.com/drugs/DB05138ExperimentalIt has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors … AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD).
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnThe approved application holder removed Merital capsules from the market on January 23, 1986. … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.
Alphaprodine
go.drugbank.com/drugs/DB13160ExperimentalIllicitCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMetixene
go.drugbank.com/drugs/DB00340ApprovedMetixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsRamoplanin
go.drugbank.com/drugs/DB04952ExperimentalRamoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.